New drug combo aims to keep ovarian cancer at bay after chemo
NCT ID NCT07225270
Summary
This large, late-stage study is testing whether adding an investigational drug called Rina-S to standard care helps control recurrent ovarian cancer for longer after second-line chemotherapy. It will enroll about 528 women whose cancer returned more than 6 months after their first platinum-based treatment. The goal is to see if Rina-S, given alone or with bevacizumab, can delay cancer progression compared to current standard options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mt. Sinai Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33140, United States
-
Osaka Medical and Pharmaceutical University Hospital
RECRUITINGTakatsuki, Osaka, Japan
Conditions
Explore the condition pages connected to this study.